INDIVIDUAL TEST 987

pTau-181

Indication

Suspicion of Alzheimer's disease or cognitive impairment.

Sample material

EDTA plasma

• Minim. volume: 0,5 mL

Transport

Within Sweden

• room temperature/frozen (stable for 48h at room temperature)

International

Method

Single Molecule Array (SIMOA)

Reference interval

< 45,0 pg/mL
The reference interval represents 99th-percentile of 150 healthy individuals.

Result

Results are reported as a concentration in pg/mL.

Interpretation

Plasma pTau-181 ≥ 45.0 pg/mL supports further investigations when Alzheimer's disease is suspected. The result should be combined with other investigations as well as clinical symptoms for the final diagnosis.

References

• Querfurth HW, LaFerla FM. N Engl J Med. 2010. Alzheimer's disease. PMID: 20107219
• Karikari TK et al. Lancet Neurol. 2020. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. PMID: 32333900
• Janelidze S et al. Nat Med. 2020. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. PMID: 32123385
• Liu HC et al. Dement Geriatr Cogn Dis Extra. 2020. Stability of Plasma Amyloid-β 1-40, Amyloid-β 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. PMID: 32308667
• Thijssen EH et al. Lancet Neurol. 2021. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. PMID: 34418401
• O'Connor A et al. Mol Psychiatry. 2021. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. PMID: 32665603

Last updated: 2024-06-26